Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 443.63
OCLS's Cash to Debt is ranked higher than
88% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. OCLS: 443.63 )
OCLS' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 443.63

Equity to Asset 0.73
OCLS's Equity to Asset is ranked higher than
80% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. OCLS: 0.73 )
OCLS' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.73
Current: 0.73

-0.21
0.73
F-Score: 5
Z-Score: -6.54
M-Score: -1.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -52.18
OCLS's Operating margin (%) is ranked higher than
52% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.59 vs. OCLS: -52.18 )
OCLS' s 10-Year Operating margin (%) Range
Min: -1202.95   Max: -7.35
Current: -52.18

-1202.95
-7.35
Net-margin (%) 47.10
OCLS's Net-margin (%) is ranked higher than
98% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.31 vs. OCLS: 47.10 )
OCLS' s 10-Year Net-margin (%) Range
Min: -1219.03   Max: 27.33
Current: 47.1

-1219.03
27.33
ROE (%) 69.18
OCLS's ROE (%) is ranked higher than
99% of the 874 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. OCLS: 69.18 )
OCLS' s 10-Year ROE (%) Range
Min: -1759.66   Max: 46.27
Current: 69.18

-1759.66
46.27
ROA (%) 38.94
OCLS's ROA (%) is ranked higher than
99% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. OCLS: 38.94 )
OCLS' s 10-Year ROA (%) Range
Min: -1518.83   Max: 22.39
Current: 38.94

-1518.83
22.39
ROC (Joel Greenblatt) (%) -696.70
OCLS's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.17 vs. OCLS: -696.70 )
OCLS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1665.34   Max: -358.75
Current: -696.7

-1665.34
-358.75
Revenue Growth (%) -8.60
OCLS's Revenue Growth (%) is ranked higher than
54% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. OCLS: -8.60 )
OCLS' s 10-Year Revenue Growth (%) Range
Min: -27.3   Max: 53.6
Current: -8.6

-27.3
53.6
» OCLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OCLS Guru Trades in

Q2 2012

OCLS Guru Trades in Q2 2012

Jim Simons 12,500 sh (+21.36%)
» More
Q3 2012

OCLS Guru Trades in Q3 2012

Jim Simons 10,200 sh (-18.4%)
» More
Q4 2012

OCLS Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OCLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 2.00
OCLS's P/E(ttm) is ranked higher than
99% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.00 vs. OCLS: 2.00 )
OCLS' s 10-Year P/E(ttm) Range
Min: 1.95   Max: 11.44
Current: 2

1.95
11.44
P/B 1.00
OCLS's P/B is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. OCLS: 1.00 )
OCLS' s 10-Year P/B Range
Min: 1   Max: 264.25
Current: 1

1
264.25
P/S 1.00
OCLS's P/S is ranked higher than
91% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. OCLS: 1.00 )
OCLS' s 10-Year P/S Range
Min: 0.89   Max: 18.2
Current: 1

0.89
18.2
EV-to-EBIT -1.52
OCLS's EV-to-EBIT is ranked higher than
63% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. OCLS: -1.52 )
OCLS' s 10-Year EV-to-EBIT Range
Min: -8.2   Max: -0.1
Current: -1.52

-8.2
-0.1
Current Ratio 1.63
OCLS's Current Ratio is ranked higher than
60% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. OCLS: 1.63 )
OCLS' s 10-Year Current Ratio Range
Min: 0.54   Max: 3.87
Current: 1.63

0.54
3.87
Quick Ratio 1.36
OCLS's Quick Ratio is ranked higher than
64% of the 890 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. OCLS: 1.36 )
OCLS' s 10-Year Quick Ratio Range
Min: 0.5   Max: 3.65
Current: 1.36

0.5
3.65

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 17.60
OCLS's Price/Net Current Asset Value is ranked higher than
81% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. OCLS: 17.60 )
OCLS' s 10-Year Price/Net Current Asset Value Range
Min: 5.62   Max: 78.87
Current: 17.6

5.62
78.87
Price/Tangible Book 1.00
OCLS's Price/Tangible Book is ranked higher than
94% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. OCLS: 1.00 )
OCLS' s 10-Year Price/Tangible Book Range
Min: 1.47   Max: 183.75
Current: 1

1.47
183.75
Price/Median PS Value 0.20
OCLS's Price/Median PS Value is ranked higher than
99% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. OCLS: 0.20 )
OCLS' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 3.95
Current: 0.2

0.22
3.95
Price/Graham Number 0.30
OCLS's Price/Graham Number is ranked higher than
99% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.77 vs. OCLS: 0.30 )
OCLS' s 10-Year Price/Graham Number Range
Min: 0.46   Max: 0.97
Current: 0.3

0.46
0.97
Earnings Yield (Greenblatt) -65.80
OCLS's Earnings Yield (Greenblatt) is ranked lower than
55% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. OCLS: -65.80 )
OCLS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -65.8   Max: 0
Current: -65.8

-65.8
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:O8Z1.Germany
Oculus Innovative Sciences Inc was incorporated under the laws of the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, it changed its name to Oculus Innovative Sciences, Inc. In December 2006, it reincorporated under the laws of the State of Delaware. The Company develops, manufactures and markets a family of tissue care products that cure infections and, through a separate mechanism of action, enhance healing while reducing the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. The Company's platform technology, called Microcyn(r), is a proprietary solution of electrically charged oxychlorine small molecules designed to treat a wide range of organisms that cause disease (pathogens). These include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA, and vancomycin-resistant Enterococcus, or VRE, in wounds, as well as Clostridium difficile (C. diff), a highly contagious bacteria spread by human contact. The Company's products compete with a variety of products used for wound cleaning, debriding and moistening, including sterile saline, and chlorhexadine-based products, and they also compete with a large number of prescription and over-the-counter products for the prevention and treatment of infections, including topical anti-infectives, such as Betadine, silver sulfadiazine, hydrogen peroxide, Dakin's solution and hypochlorous acid, and topical antibiotics, such as Neosporine, Mupirocin and Bacitracin. Government authorities in the United States at the federal, state and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics and medical devices.
» More Articles for OCLS

Headlines

Articles On GuruFocus.com
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 04 2011 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Nov 04 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 20,000 Shares Dec 09 2009 
Weekly CFO Buys Highlight: Information Services Group Inc., BioFuel Energy Corp., Oculus Innovative Nov 22 2009 
Weekly CFO Buys Highlight: Information Services Group, Magnum Hunter Resources, Columbia Laboratorie Nov 15 2009 
Oculus Innovative Sciences Inc. (OCLS) CFO Robert E Miller buys 13,000 Shares Nov 12 2009 

More From Other Websites
OCULUS INNOVATIVE SCIENCES, INC. Financials Nov 21 2014
10-Q for Oculus Innovative Sciences, Inc. Nov 15 2014
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 13 2014
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015 Nov 13 2014
Oculus Innovative Sciences Commercializes Microcyn®-Based Solution and Hydrogel for Treatment of... Nov 11 2014
Oculus Innovative Sciences Commercializes Microcyn(R)-Based Solution and Hydrogel for Treatment of... Nov 11 2014
Oculus Innovative Sciences Receives European CE Mark for New Microcyn®-Based Scar Management... Nov 04 2014
Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Scar Management... Nov 04 2014
Dilemma: Should companies reinvest or buyback stock? Oct 30 2014
Oculus Innovative Sciences Announces Fiscal Second Quarter 2015 Financial Results and Conference... Oct 30 2014
Oculus Innovative Sciences Receives European CE Mark for New Microcyn®-Based Atopic Dermatitis... Oct 30 2014
Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Atopic Dermatitis... Oct 30 2014
Oculus Innovative Sciences Announces Fiscal Second Quarter 2015 Financial Results and Conference... Oct 30 2014
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of Four New... Sep 16 2014
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Sep 12 2014
Oculus Innovative Sciences Introduces Microcyn(R)-Based Over-the-Counter Advanced Scar Management... Sep 10 2014
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 10-Q, Quarterly Report Aug 12 2014
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Aug 01 2014
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 10-K, Annual Report Jun 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK